Oracle Falls on Disappointing Cloud Sales; Gemini Rallies; Eli Lilly Jumps
Dec 11, 2025
Oracle's latest cloud sales disappointed investors despite significant growth in its infrastructure business, as rising costs from AI data centers weigh on revenues. Meanwhile, Gemini Space Station saw its shares rally after gaining approval for a derivatives exchange, expanding its footprint in prediction markets. In other news, Eli Lilly's groundbreaking obesity drug showed impressive results in a late-stage study, sparking discussions on health and fitness.
03:30
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
insights INSIGHT
Heavy AI CapEx Outpaces Cloud Revenue
Oracle is spending heavily on AI data centers and raised 2026 capex outlook by $15 billion to $50 billion.
Cloud revenue growth lagged investor expectations despite big infrastructure gains and major customers like ByteDance and Meta.
insights INSIGHT
Gemini Enters Prediction Markets
Gemini Space Station's derivatives-exchange approval lets it enter prediction markets for events like politics and sports.
The approval by the CFTC drove the stock higher as Gemini plans event-contract trading for U.S. customers.
insights INSIGHT
New Obesity Shot Shows Large Weight Loss
Eli Lilly's experimental retatrutide produced ~23% average weight loss over 68 weeks in a late-stage trial.
The drug also delivered large reductions in knee pain tied to obesity, beating expectations and lifting Lilly shares.
Get the Snipd Podcast app to discover more snips from this episode
- Shares of Oracle (ORCL) fell in early trading after the company reported a jump in spending on AI data centers and other equipment, rising outlays that are taking longer to translate into cloud revenue than investors want. Fiscal second-quarter cloud sales increased 34% to $7.98 billion, while revenue in the company’s closely watched infrastructure business gained 68% to $4.08 billion. Both numbers fell just short of analysts’ estimates. Known for its database software, Oracle has recently found success in the competitive cloud computing market. It’s engaging in a massive data center build-out to power AI work for OpenAI and also counts companies such as ByteDance Ltd.’s TikTok and Meta Platforms Inc. as major cloud customers. - Shares of Gemini Space Station Inc. (GEMI) rallied after the company's application for a derivatives exchange was approved by the Commodity Futures Trading Commission Wednesday, in a move that will allow the company to join the fast-growing field of prediction markets. Gemini, co-founded by billionaire twin brothers Tyler and Cameron Winklevoss, will soon allow existing US customers to trade event contracts on its website and mobile app, the company said in a blog post. In a regulatory filing prior to its initial public offering, the firm included prediction markets on “economic, financial, political and sports forecasts” among the list of products it was interested in trading. - Shares of Eli Lilly & Co. (LLY) jumped in the premarket session after the company's next-generation obesity shot helped patients lose almost a quarter of their body weight, potentially making the experimental drug the most potent weight loss medicine yet. The late-stage study was designed to measure weight loss and pain associated with knee osteoarthritis, a condition closely linked to obesity. Patients on the highest dose of the drug — called retatrutide — lost more than 23% of their body weight in 68 weeks, Lilly said in a statement Thursday.
Stock Movers